Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia.

Trial Profile

Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jun 2013 Results will be presented at the 2013 European Hematology Association (EHA) Meeting according to a TG Therapeutics media release.
    • 27 Apr 2012 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual patient number (33) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top